(Reuters) – The advisory committee to the European Union’s drug regulator on Thursday recommended expanding the use of Novavax Inc’s COVID-19 vaccine for adolescents aged 12 to 17 years.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila)
